GET THE APP

Biclonal Gammopathy in a Patient taking Efalizumab for the Treatment of Psoriasis | Abstract
Journal of Hematology & Thromboembolic Diseases

Journal of Hematology & Thromboembolic Diseases
Open Access

ISSN: 2329-8790

+44 20 3868 9735

Abstract

Biclonal Gammopathy in a Patient taking Efalizumab for the Treatment of Psoriasis

Antonia Fthenakis, Kurt S Wenk, Alison Ehrlich and Jeanny B Aragon-Ching

We report a patient who developed biclonal gammopathy of undetermined significance during treatment with
efalizumab for psoriasis. This plasma cell disorder was found during the evaluation of the patient’s complaint of mild lower extremity paresthesia. The gammopathy spontaneously remitted following cessation of therapy and has not recurred to date. Given the increasing use and development of biological agents for the treatment of psoriasis and  other disorders, this finding and the mechanisms by which it may have occurred is of clinical significance.